<?xml version='1.0' encoding='utf-8'?>
<document id="32056160"><sentence text="Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists." /><sentence text="Coronary artery disease remains the major cause of mortality worldwide" /><sentence text=" Antiplatelet drugs such as acetylsalicylic acid and P2Y12 receptor antagonists are cornerstone treatments for the prevention of thrombotic events in patients with coronary artery disease"><entity charOffset="28-48" id="DDI-PubMed.32056160.s3.e0" text="acetylsalicylic acid" /></sentence><sentence text=" Clopidogrel has long been the gold standard but has major pharmacological limitations such as a slow onset and long duration of effect, as well as weak platelet inhibition with high inter-individual pharmacokinetic and pharmacodynamic variability"><entity charOffset="1-12" id="DDI-PubMed.32056160.s4.e0" text="Clopidogrel" /><entity charOffset="31-35" id="DDI-PubMed.32056160.s4.e1" text="gold" /><pair ddi="false" e1="DDI-PubMed.32056160.s4.e0" e2="DDI-PubMed.32056160.s4.e0" /><pair ddi="false" e1="DDI-PubMed.32056160.s4.e0" e2="DDI-PubMed.32056160.s4.e1" /></sentence><sentence text=" There has been a strong need to develop potent P2Y12 receptor antagonists with more favorable pharmacological properties" /><sentence text=" Prasugrel and ticagrelor are more potent and have a faster onset of action; however, they have shown an increased bleeding risk compared with clopidogrel"><entity charOffset="1-10" id="DDI-PubMed.32056160.s6.e0" text="Prasugrel" /><entity charOffset="15-25" id="DDI-PubMed.32056160.s6.e1" text="ticagrelor" /><entity charOffset="143-154" id="DDI-PubMed.32056160.s6.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.32056160.s6.e0" e2="DDI-PubMed.32056160.s6.e0" /><pair ddi="false" e1="DDI-PubMed.32056160.s6.e0" e2="DDI-PubMed.32056160.s6.e1" /><pair ddi="false" e1="DDI-PubMed.32056160.s6.e0" e2="DDI-PubMed.32056160.s6.e2" /><pair ddi="false" e1="DDI-PubMed.32056160.s6.e1" e2="DDI-PubMed.32056160.s6.e1" /><pair ddi="false" e1="DDI-PubMed.32056160.s6.e1" e2="DDI-PubMed.32056160.s6.e2" /></sentence><sentence text=" Cangrelor is highly potent and has a very rapid onset and offset of effect; however, its indication is limited to P2Y12 antagonist-naÃ¯ve patients undergoing percutaneous coronary intervention" /><sentence text=" Two novel P2Y12 receptor antagonists are currently in clinical development, namely vicagrel and selatogrel" /><sentence text=" Vicagrel is an analog of clopidogrel with enhanced and more efficient formation of its active metabolite"><entity charOffset="26-37" id="DDI-PubMed.32056160.s9.e0" text="clopidogrel" /></sentence><sentence text=" Selatogrel is characterized by a rapid onset of action following subcutaneous administration and developed for early treatment of a suspected acute myocardial infarction" /><sentence text=" This review article describes the clinical pharmacology profile of marketed P2Y12 receptor antagonists and those under development focusing on pharmacokinetic, pharmacodynamic, and drug-drug interaction liability" /><sentence text="" /></document>